The US Food and Drug Administration (FDA) has issued a new safety warning about a potential increased risk of a rare but serious eye condition associated with widely prescribed GLP-1 medications, including Ozempic, Wegovy, Mounjaro and Zepbound. The condition can cause sudden, painless vision loss and, in some cases, permanent damage to eyesight.
FDA has announced new safety labelling requirements for GLP-1 receptor agonist (GLP-1 RA) medications, which are commonly prescribed for weight management and type 2 diabetes.
In its safety communication dated November 9, 2026, the FDA highlighted a potential association between these medications and a rare eye disorder called non-arteritic anterior ischemic optic neuropathy (NAION). The condition occurs when blood flow to the optic nerve is reduced, potentially resulting in sudden vision impairment or permanent vision loss.
The agency is now requiring manufacturers of all GLP-1 receptor agonist medications to include information about this potential risk in the Warnings and Precautions section of their drug labels.
Which Popular Weight-Loss Medications Are Affected?
The FDA’s warning applies to the broader class of GLP-1 receptor agonist medications, rather than a single brand.
Some of the widely used medications covered by the safety communication include:
- Ozempic (semaglutide): Primarily prescribed for type 2 diabetes.
- Wegovy (semaglutide): Approved for chronic weight management and certain other medical indications.
- Mounjaro (tirzepatide): Prescribed for type 2 diabetes.
- Zepbound (tirzepatide): Approved for chronic weight management and certain other conditions.
- Saxenda (liraglutide): Used for weight management.
- Victoza (liraglutide): Used for type 2 diabetes.
- Trulicity (dulaglutide): Used for type 2 diabetes.
The FDA’s list also includes oral medications such as Rybelsus and newer treatments such as Foundayo.
Although tirzepatide acts on both GIP and GLP-1 receptors, it is included in the FDA’s broader safety assessment.
What Is NAION and How Can It Affect Vision?
Non-arteritic anterior ischemic optic neuropathy, commonly known as NAION, is an eye condition caused by insufficient blood supply to the front portion of the optic nerve.
The optic nerve plays a crucial role in transmitting visual information from the eyes to the brain. When its blood supply is disrupted, the resulting damage can lead to sudden vision loss.
One of the concerning features of NAION is that it is typically painless. Patients may first notice a significant change in their vision when they wake up in the morning.
Depending on the severity of the condition, vision loss can be permanent. Although some patients may experience limited improvement, recovery is often incomplete.
NAION can affect one eye initially, and individuals who have experienced it in one eye may have an increased risk of developing the condition in the other eye.
What Did the FDA’s Investigation Find?
The FDA evaluated several sources of evidence, including clinical trial data, animal studies, post-marketing safety reports and observational research.
A major part of its assessment involved a meta-analysis of 126 clinical trials involving more than 134,000 participants.
The analysis identified the following rates of NAION:
- GLP-1 medication users: 6.4 cases per 100,000 person-years.
- Comparison group: 3.8 cases per 100,000 person-years.
The findings suggest a higher incidence of NAION among people receiving GLP-1 medications compared with those receiving placebo or certain other glucose-lowering treatments.
The FDA also conducted a retrospective study using its Sentinel real-world evidence database. Although the study found no statistically significant increase in NAION risk compared with SGLT-2 inhibitors, an increased risk was observed when GLP-1 medications were compared with DPP-4 inhibitors.
The agency also reviewed published observational studies that generally reported an association between GLP-1 treatment and NAION in patients with type 2 diabetes.
Based on the combined evidence, the FDA concluded that there is a potential increased risk of this rare eye condition among people taking GLP-1 medications.
However, the exact biological mechanism behind this possible association remains unclear, and the findings do not establish that these medications directly cause NAION.
Warning Signs Patients Should Not Ignore
The FDA has advised patients and caregivers to remain alert to changes in vision while using GLP-1 medications.
Symptoms associated with NAION may include:
- Sudden, painless loss of vision in one eye.
- Blurred or hazy vision.
- Dark spots or blind spots in the visual field.
- Missing portions of vision or tunnel vision.
- Distorted colour perception.
- Reduced sharpness of central vision.
These symptoms require immediate medical attention.
Patients experiencing sudden changes in vision should contact a healthcare professional immediately and seek urgent ophthalmological evaluation. Early assessment is important because NAION can cause lasting damage to the optic nerve.
Who May Be at Higher Risk?
NAION is a rare condition, but certain underlying health conditions may increase an individual’s susceptibility.
According to the FDA, potential risk factors include:
- Diabetes.
- High blood pressure.
- Smoking.
- Obstructive sleep apnea.
- Anemia.
- Kidney disease.
These conditions may affect blood circulation or the health of the optic nerve.
People with these risk factors should discuss their medical history with their healthcare providers before starting or continuing GLP-1 treatment.
Should Patients Stop Taking Ozempic, Wegovy or Other GLP-1 Medications?
The FDA’s announcement does not mean that everyone taking GLP-1 medications should discontinue treatment.
These medicines have demonstrated important benefits in managing type 2 diabetes, supporting weight reduction and, for certain approved products and patient groups, reducing cardiovascular and kidney-related health risks.
Patients should not stop their prescribed medication or change their dosage without consulting their treating healthcare professional.
However, anyone who develops symptoms suggestive of NAION should seek immediate medical evaluation.
For patients who receive a confirmed diagnosis of NAION, the FDA advises discussing whether to continue or discontinue GLP-1 treatment with their healthcare provider. Healthcare professionals should consider discontinuing the medication in patients who develop NAION unless the benefits of continued treatment clearly outweigh the risks.
What Does This Mean for the Future of Weight-Loss Treatments?
GLP-1 medications have transformed the treatment landscape for obesity and type 2 diabetes. Their ability to regulate appetite, improve blood glucose control and support clinically meaningful weight reduction has made them increasingly popular worldwide.
However, their expanding use also highlights the importance of long-term safety monitoring.
The FDA’s latest warning reinforces the need for patients and healthcare professionals to understand both the benefits and potential risks associated with these medications.
The important message is not to create unnecessary fear around GLP-1 treatments, but to encourage informed prescribing, appropriate patient monitoring and prompt attention to unusual symptoms.
For people using these medications, awareness is essential. Sudden, painless changes in vision should never be ignored, particularly when they may indicate a potentially serious condition affecting the optic nerve.
Leave a comment